{"id":"NCT01163032","sponsor":"Vanda Pharmaceuticals","briefTitle":"Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder","officialTitle":"A Multicenter, Randomized, Double-Mask, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of 20 mg Tasimelteon Versus Placebo in Totally Blind Subjects With N24HSWD Followed by an OLE Phase","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-08","primaryCompletion":"2012-11","completion":"2012-11","firstPosted":"2010-07-15","resultsPosted":"2014-10-16","lastUpdate":"2014-10-16"},"enrollment":136,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Non-24-Hour Sleep-Wake Disorder"],"interventions":[{"type":"DRUG","name":"tasimelteon","otherNames":["VEC-162"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"tasimelteon","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of a six month double-mask treatment of tasimelteon or placebo in male and female subjects with Non-24-Hour Sleep-Wake Disorder","primaryOutcome":{"measure":"Proportion of Patients Entrained as Assessed by Urinary aMT6","timeFrame":"1 month","effectByArm":[{"arm":"Tasimelteon (Randomized)","deltaMin":20,"sd":null},{"arm":"Placebo (Randomized)","deltaMin":2.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":28,"countries":["United States","Germany"]},"refs":{"pmids":["26466871"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":42},"commonTop":["Headache","Nasopharyngitis","Urinary tract infection","Alanine aminotransferase increased","Asparate aminotransferase increased"]}}